Baker Bros. Advisors Reduces $71K in Opthea Limited ($OPTEY)
Key Points
- Baker Bros. Advisors changed its Opthea Limited ($OPTEY) stake by 100% last quarter, cutting to 0 shares.
- $OPTEY last traded around $0.03.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baker Bros. Advisors reduced its position in Opthea Limited ($OPTEY), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Opthea Limited after selling 2,087,320 shares during the quarter.
Opthea Limited Stock Up 21.4%
Shares of Opthea Limited ($OPTEY) traded around $0.03 on Sunday, up 21.4% for the day.
Opthea Limited Earnings
About Opthea Limited
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Get Opthea Limited alerts
New 13F filings, insider trades, and analyst moves on $OPTEY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.